Drugs / IBR854
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06001684 | Sep 2023 → Dec 2024 | cancer | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07087158 | Sep 2025 → Dec 2026 expected | renal cell carcinoma | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBR854 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06001684 ↗ |
| Route | Intravenous | “Patients received intravenous IBR854 in a 3 + 3 escalation design.” PMID 42406083 ↗ Jul 2026 |